Global X FTSE Southeast Asia ETF vs Cassava Sciences Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.47, while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| ASEA | FLNA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $4.64 |
52-Week Low | $16.86 | $0.87 |
Market Cap | — | $47.75M |
Enterprise Value | — | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
ASEA trades at $21.53, up 1.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows uniform support and resistance at $21. Key financial ratios are unavailable, but a dividend of $0.41 is scheduled for July 2026. Recent business developments and earnings data are not provided, limiting fundamental assessment.
The outlook is cautiously optimistic due to strong technical momentum, though the absence of current financial metrics and news increases uncertainty. Investment opportunity hinges on upcoming financial disclosures, while risks include data gaps and market volatility. Investors should await earnings reports for clearer valuation insights.
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
Trailing returns across standard periods
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →